Cencora, Inc. (NYSE:COR) Shares Sold by State of Tennessee Department of Treasury

State of Tennessee Department of Treasury lowered its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 4.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,225 shares of the company's stock after selling 1,616 shares during the period. State of Tennessee Department of Treasury's holdings in Cencora were worth $7,240,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. TD Waterhouse Canada Inc. lifted its holdings in Cencora by 1.5% in the 4th quarter. TD Waterhouse Canada Inc. now owns 79,853 shares of the company's stock valued at $17,941,000 after purchasing an additional 1,192 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Cencora by 124.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,115 shares of the company's stock worth $2,048,000 after buying an additional 5,047 shares in the last quarter. Transce3nd LLC acquired a new position in Cencora during the fourth quarter worth about $122,000. Trajan Wealth LLC grew its stake in Cencora by 5.5% during the 4th quarter. Trajan Wealth LLC now owns 112,446 shares of the company's stock valued at $25,264,000 after acquiring an additional 5,885 shares in the last quarter. Finally, MML Investors Services LLC raised its holdings in Cencora by 2.8% in the 4th quarter. MML Investors Services LLC now owns 87,852 shares of the company's stock valued at $19,739,000 after acquiring an additional 2,402 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Activity

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the transaction, the executive vice president now directly owns 14,665 shares of the company's stock, valued at $3,934,326.20. The trade was a 21.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,223 shares of company stock worth $13,580,967. Corporate insiders own 10.80% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Finally, UBS Group increased their price target on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and a consensus price target of $289.09.

Cencora Trading Up 0.5 %

NYSE:COR traded up $1.57 during trading hours on Wednesday, reaching $291.74. 225,945 shares of the stock were exchanged, compared to its average volume of 1,695,727. The business has a 50-day moving average of $269.87 and a two-hundred day moving average of $250.27. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $296.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market capitalization of $56.57 billion, a price-to-earnings ratio of 41.47, a PEG ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. Cencora's payout ratio is currently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.